NCT06026592 Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
| NCT ID | NCT06026592 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Acute Kidney Injury |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-09-02 |
| Primary Completion | 2026-07-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-09-02 with a primary completion date of 2026-07-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a potential diagnostic tool to monitor the rejection status of the kidney transplant. It has been suggested that dd-cfDNA is increasing in the blood of kidney transplant patient presenting a graft rejection. In this project, investigators proposed a different approach to predict and characterize kidney transplant rejection/dysfunction based on the quantification of epigenetic signatures present on the donor-cell-free DNA. In 2018, Moss et al. develops a deconvolution model capable of identifying the tissue origin of circulating DNA by taking advantage of its epigenetic properties. The study confirmed that the cell-free DNA circulating in healthy subjects comes mainly from blood cells and endothelial cells, but not from kidney cells. In this study, researchers investigate the evolution of blood renal-specific cell-free DNA amount in patient with chronic kidney disease before and after the transplantation surgery by testing a set of renal-specific epigenetic markers. The purpose of this study is to identify the biological noise of "native kidney" on renal-specific cell-free DNA and to compare it with signal coming from "transplanted kidney".
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * With end-stage renal failure * Summoned for a kidney transplant at Pitié Salpêtrière Hospital * Having been informed of the study and not objecting to the study having given free and informed written consent for the genetic analysis * Benefiting from a social security scheme (excluding AME) Exclusion Criteria: Under legal protective measures (curatorship or guardianship, under judicial safeguard).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06026592 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Kidney Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06026592 currently recruiting?
Yes, NCT06026592 is actively recruiting participants. Contact the research team at sarah.drouin@aphp.fr for enrollment information.
Where is the NCT06026592 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06026592 clinical trial?
NCT06026592 is sponsored by Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.